CardioPulmonary resuscitation with <i>Ar</i>gon (CP<i>Ar)</i>: A protocol for a randomised controlled multicentre clinical trial.

ABSTRACT:

Aims

The CardioPulmonary resuscitation with Argon (CPAr) trial evaluates the clinical neuroprotective efficacy and safety of post-resuscitation ventilation with a 70/30 argon/oxygen (Ar/O₂) gas mixture compared to standard care ventilation with 30% O₂ in unconscious adults resuscitated from out-of-hospital cardiac arrest (OHCA).

Methods

CPAr is an allocation-concealed, single-blinded, multi-centre, phase II, pre-marketing, randomised controlled trial (RCT). The study aims to recruit 120 patients across tertiary intensive care units (ICUs) in Italy. Eligible participants are unconscious adult OHCA survivors with a shockable presenting rhythm. Upon ICU admission, patients are individually randomised in a 1:1 ratio to receive either 4-h venti

SUBMITTER: Ristagno G 

PROVIDER: S-EPMC12513211 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature